FIGURE 1

A498

Cakl-1

FIGURE 2A

FIGURE 2B

FIGURE 3A

FIGURE 3B

FIGURE 4A

Legend:
- Saline
- SEQ ID NO:1/2.5mg
- SEQ ID NO:3/2.5mg
- Intron A10^5
- SEQ ID NO:1/2.5mg+IntronA10^5
- SEQ ID NO:3/2.5mg+IntronA10^5

n=10

Y-axis: Tumor Size(mm^3)

X-axis: Days after Tumor Injection

FIGURE 4B

FIGURE 5A

FIGURE 5B

FIGURE 6A

Tumor Size (mm3)

Days After Tumor Injection

Saline-iv
Saline-it
SEQ ID NO:1-1mg/kg,iv
SEQ ID NO:1-2.5mg/kg,iv
Intron A-1000units,it
Intron A-100000units,it
SEQ ID NO:1-1mg/kg, iv+IntronA10³units, it
SEQ ID NO:1-1mg/kg, iv+IntronA10⁵ units, it
SEQ ID NO:1-2.5mg/kg, iv+IntronA10³ units, it
SEQ ID NO:1-2.5mg/kg, iv+IntronA10⁵ units, it

FIGURE 6B

FIGURE 7A

FIGURE 7B

FIGURE 8A

FIGURE 8B

Tumor Weight(mg)

FIGURE 9

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice Treated with Combination Therapy

FIGURE 10

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice

* means P < 0.05

Tumor Weight (mg)

CPT-11+SEQ ID NO:1

SEQ ID NO:1

CPT-11

Saline Control

# FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice

FIGURE 12

Growth of Human Adenocarcinoma (HT-29) in CD-1 Nude Mice

FIGURE 13

FIGURE 14

**Weight of Human Prostate Carcinoma (PC-3)
in SCID Mice**

FIGURE 15

Weight of Human Prostate Carcinoma(DU145) in SCID Mice

A

B

FIGURE 16

Weight of Human Melanoma (A2058) in CD-1 Nude Mice

FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

24/34

FIGURE 18

Growth of Human Ovary Adenocarcinoma (SK-OV-3) in CD-1 Nude Mice

FIGURE 19

A **Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice**

B **Weight of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice**

FIGURE 20

Growth of Human Cervix Epitheloid Carcinoma
(Hela S3-HU-Resistance) in SCID Mice

A

Weight of Human Cervix Epitheloid Carcinoma
(Hela S3-HU-Resistance) in SCID Mice

B

27/34

FIGURE 21

**Weight of Human Cisplatin-Resistant Breast Adenocarcinoma
Implanted at the Fat Pad of SCID Mice**

Statistical Analysis:	P value
Saline : Cisplatin	0.0834
Saline : Taxol	<0.0001
Saline : SEQ ID NO:1	<0.0001
SEQ ID NO:1 : Cisplatin	0.0007
SEQ ID NO:1 : Taxol	0.9547

FIGURE 22

**Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17·
SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+ SEQ ID NO:1
(Orthotopical transplant)**

A

B

SEQ ID NO:1: Taxol P=0.0133
SEQ ID NO:1: SEQ ID NO:1+Taxol P=0.0003
Taxol : SEQ ID NO:1+Taxol P<0.0001

C

FIGURE 23

**Weight of Human Taxol-Resistant Breast Adenocarcinoma
(MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice**

FIGURE 24

Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1) in SCID Mice

A

Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1) in SCID Mice

B

FIGURE 25

**Growth of Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**

A

**Weight of Human Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**

B

FIGURE 26

Growth of Human Multi-Drug Resistance Colon
Adenocarcinoma (LS513) in SCID Mice

A

B

Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513)
In SCID Mice

C

FIGURE 27

>gi|4557844|ref|NM_001034.1| Homo sapiens ribonucleotide reductase M2
polypeptide (RRM2), mRNA

```
CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGCCGGGGCACCAAAGCC
AATGGGAAGGGCCGGGAGCGCGCGGCGCGGGGAGATTTAAAGGCTGCTGGAGTGAGGGGTCGCCCGTGCAC
CCTGTCCCAGCCGTCCTGTCCTGGCTGCTCGCTCTGCTTCGCTGCGCCTCCACTATGCTCTCCCTCCGTG
TCCCGCTCGCGCCCATCACGGACCCGCAGCAGCTGCAGCTCTCGCCGCTGAAGGGGCTCAGCTTGGTCGA
CAAGGAGAACACGCCGCCGGCCCTGAGCGGGACCCGCGTCCTGGCCAGCAAGACCGCGAGGAGGATCTTC
CAGGAGCCCACGGAGCCGAAAACTAAAGCAGCTGCCCCCGGCGTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCCGCCGCTTTGTCATCTTCCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGC
TTCCTTTTGGACCGCCGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAACCCGAG
GAGAGATATTTTATATCCCATGTTCTGGCTTTCTTTGCAGCAAGCGATGGCATAGTAAATGAAAACTTGG
TGGAGCGATTTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGTTTCTATGGCTTCCAAATTGCCATGGA
AAACATACATTCTGAAATGTATAGTCTTCTTATTGACACTTACATAAAAGATCCCAAAGAAAGGGAATTT
CTCTTCAATGCCATTGAAACGATGCCTTGTGTCAAGAAGAAGGCAGACTGGGCCTTGCGCTGGATTGGGG
ACAAAGAGGCTACCTATGGTGAACGTGTTGTAGCCTTTGCTGCAGTGGAAGGCATTTTCTTTTCCGGTTC
TTTTGCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCTGGCCTCACATTTTCTAATGAACTTATT
AGCAGAGATGAGGGTTTACACTGTGATTTTGCTTGCCTGATGTTCAAACACCTGGTACACAAACCATCGG
AGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCGGATAGAACAGGAGTTCCTCACTGAGGCCTTGCC
TGTGAAGCTCATTGGGATGAATTGCACTCTAATGAAGCAATACATTGAGTTTGTGGCAGACAGACTTATG
CTGGAACTGGGTTTTAGCAAGGTTTTCAGAGTAGAGAACCCATTTGACTTTATGGAGAATATTTCACTGG
AAGGAAAGACTAACTTCTTTGAGAAGAGAGTAGGCGAGTATCAGAGGATGGGAGTGATGTCAAGTCCAAC
AGAGAATTCTTTTACCTTGGATGCTGACTTCTAAATGAACTGAAGATGTGCCCTTACTTGGCTGATTTTT
TTTTTCCATCTCATAAGAAAAATCAGCTGAAGTGTTACCAACTAGCCACACCATGAATTGTCCGTAATGT.
TCATTAACAGCATCTTTAAAACTGTGTAGCTACCTCACAACCAGTCCTGTCTGTTTATAGTGCTGGTAGT
ATCACCTTTTGCCAGAAGGCCTGGCTGGCTGTGACTTACCATAGCAGTGACAATGGCAGTCTTGGCTTTA
AAGTGAGGGGTGACCCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGTCCTTTAACCAGCACAGCCAGT
TAAAAGATGCAGCCTCACTGCTTCAACGCAGATTTTAATGTTTACTTAAATATAAACCTGGCACTTTACA
AACAAATAAACATTGTTTTGTACTCACGGCGGCGATAATAGCTTGATTTATTTGGTTTCTACACCAAATA
CATTCTCCTGACCACTAATGGGAGCCAATTCACAATTCACTAAGTGACTAAAGTAAGTTAAACTTGTGTA
GACTAAGCATGTAATTTTTAAGTTTTATTTTAATGAATTAAAATATTTGTTAACCAACTTTAAAGTCAGT
CCTGTGTATACCTAGATATTAGTCAGTTGGTGCCAGATAGAAGACAGGTTGTGTTTTTATCCTGTGGCTT
GTGTAGTGTCCTGGGATTCTCTGCCCCCTCTGAGTAGAGTGTTGTGGGATAAAGGAATCTCTCAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAATTTAGGGGTGATCTGGGCCTTCATATGTGTGAGAAGCCGTTT
CATTTTATTTCTCACTGTATTTTCCTCAACGTCTGGTTGATGAGAAAAAATTCTTGAAGAGTTTTCATAT
GTGGGAGCTAAGGTAGTATTGTAAAAATTTCAAGTCATCCTTAAACAAAATGATCCACCTAAGATCTTGCC
CCTGTTAAGTGGTGAAATCAACTAGAGGTGGTTCCTACAAGTTGTTCATTCTAGTTTTGTTTGGTGTAAG
TAGGTTGTGTGAGTTAATTCATTTATATTTACTATGTCTGTTAAATCAGAAATTTTTTATTATCTATGTT
CTTCTAGATTTTACCTGTAGTTCATAAAAAAAAAAAAAAAAAAAAAAAAAAAA
```